Judge signs off on Teva's $35M settlement over delayed inhaler generics

asthma inhalersNegative

AI Analysis

Summary

A Massachusetts federal judge approved a $35 million settlement between Teva Pharmaceuticals and healthcare funds over allegations the company delayed generic inhaler launches, causing elevated prices. The settlement resolves antitrust-related claims regarding delayed generic asthma inhalers.

Outcome Details

settlement approved

Importance:4/10

Sentiment:

-0.60

settlementgenericslitigationinhalerpricing

Related Companies

$TEVA

Read the original article

Published by Endpoints News on August 6, 2026 7:04 PM

Read Original